| Rocky Mountain Kid Therapy | |
|
11154 Huron St, #101, Northglenn, CO 80234-2329 | |
| (303) 886-5348 | |
| (303) 562-2415 |
| Full Name | Rocky Mountain Kid Therapy |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist |
| Location | 11154 Huron St, Northglenn, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992764583 | NPI | - | NPPES |
| 89832337 | Medicaid | CO | |
| 52605272 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 1035295 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rocky Mountain Kid Therapy 11154 Huron St, #101, Northglenn, CO 80234-2329 Ph: (303) 886-5348 | Rocky Mountain Kid Therapy 11154 Huron St, #101, Northglenn, CO 80234-2329 Ph: (303) 886-5348 |
News Archive
Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia.
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.
A special edition of UNICEF's annual State of the World's Children report, released 20 years after the U.N. Convention on the Rights of the Child, shows that "fewer youngsters are dying and more are going to school - but an estimated 1 billion still lack services essential to their survival and development," the Associated Press reports.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.
› Verified 3 days ago
Anna Shaver, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11154 Huron St Ste 101, Northglenn, CO 80234 Phone: 720-381-0624 | |
Rachel Pinkus, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11160 Huron St Ste 200, Northglenn, CO 80234 Phone: 720-872-6472 | |
Ms. Kathleen Celmer, COTA/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10767 Cook St, Northglenn, CO 80233 Phone: 303-929-0489 | |
Stephanie Aleen Killpack, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11154 Huron St Ste 101, Northglenn, CO 80234 Phone: 720-381-0624 | |
Christina Young, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10701 Melody Dr Ste 100, Northglenn, CO 80234 Phone: 720-872-6472 | |
Lauren Helbling, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11160 Huron St Ste 200, Northglenn, CO 80234 Phone: 720-872-6472 | |
Alyssa Cure, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11160 Huron Street, Suite 200, Northglenn, CO 80234 Phone: 720-212-8156 |